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Background: Recovery after a major stroke is usually limited, but cell therapy for patients with fixed neurologic
deficits is emerging. Several recent clinical trials have investigated mesenchymal stem cell (MSC) therapy for
patients with ischemic stroke. We previously reported the results of a controlled trial on the application of
autologous MSCs in patients with ischemic stroke with a long-term follow-up of up to 5 years (the ‘STem cell
Application Researches and Trials In NeuroloGy’ (STARTING) study). The results from this pilot trial are challenging,
but also raise important issues. In addition, there have been recent efforts to improve the safety and efficacy of
MSC therapy for stroke.
Methods and design: The clinical and preclinical background and the STARTING-2 study protocol are provided.
The trial is a prospective, randomized, open-label, blinded-endpoint (PROBE) clinical trial. Both acute and chronic
stroke patients will be selected based on clinical and radiological features and followed for 3 months after MSC
treatment. The subjects will be randomized into one of two groups: (A) a MSC group (n = 40) or (B) a control
group (n = 20). Autologous MSCs will be intravenously administered after ex vivo culture expansion with
autologous ischemic serum obtained as early as possible, to enhance the therapeutic efficacy (ischemic
preconditioning). Objective outcome measurements will be performed using multimodal MRI and detailed
functional assessments by blinded observers.
Discussion: This trial is the first to evaluate the efficacy of MSCs in patients with ischemic stroke. The results may
provide better evidence for the effectiveness of MSC therapy in patients with ischemic stroke.
Trial registration: This trial was registered with ClinicalTrials.gov, number NCT01716481.
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Stroke is a leading cause of death, along with cancer and
coronary heart disease, and the most common cause of
physical disability in adults. Moreover, stroke causes a
greater loss of healthy life years, as measured in disability-
adjusted life years, than other illnesses [1]. Thrombolytic* Correspondence: nmboy@unitel.co.kr
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reproduction in any medium, provided the ortherapy is currently the only available stroke treatment,
though it can only be applied to a limited population of
patients. Various approaches to protect the brain from is-
chemic damage have met with limited success in clinical
practice. Consequently, a large proportion of stroke sur-
vivors are left with severe disabilities.
To date, relatively little attention has been given to re-
storative therapy after stroke. Although rehabilitation is
important for maximizing functional recovery in the
early stages after stroke, no definitive treatment can re-
pair lost brain function. Cell-based therapy is one of the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and has recently been evaluated as a regenerative strat-
egy for patients with fixed neurologic deficits after
stroke.
Clinical protocols must be established based on recent
advances in understanding the mechanisms of stem cells
in recovery after stroke. Here, we discuss the current
status and important issues in the application of stem
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Application Researches and Trials In NeuroloGy-2’
(STARTING-2).
Current cell-based therapy in stroke: trials and issues
Several recent clinical trials have used stem cells in
stroke (Table 1) [2-9], and the results from these trials
have raised important issues. Specifically, these trials var-
ied in patient characteristics, cell therapy timing, doseenchymal stem cells
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addition, many factors that could be critical for trans-
plantation success including the location/extension of le-
sions were not adequately considered [10]. Finally, the
assessment of functional improvement, the occurrence
of adverse effects, and pretreatment screening tests for
safety were not standardized.
Patient selection
Selection of candidate patients for cell-based therapies
based on factors such as stroke severity, lesion location,
and stroke chronicity should be optimized. Because of
the experimental nature of this treatment, clinical trials
of cell-based therapies for stroke have studied patients
with severe disabilities or chronic stroke, sometimes sev-
eral years after stroke onset. However, it may be difficult
to demonstrate therapeutic benefit in these cases [11]. In
contrast, patients with minor strokes might not be can-
didates because of the possible risks from these experi-
mental treatments.
Most experimental stem-cell-based therapies for stroke
are tested in animal models with middle cerebral artery
(MCA) occlusions [12]. Stimulation of stroke-induced
subventricular neurogenesis and migration of newly
formed cells into adjacent ischemic areas has been sug-
gested as one of the important mechanisms of cell ther-
apy and is associated with functional recovery in MCAFigure 1 Discrepancy between preclinical and clinical trials. (A) MRI fin
(90 minutes) middle cerebral artery (MCA) occlusion shows large cortical an
Stimulated neurogenesis after application of human mesenchymal stem ce
immunostaining in the subventricular zone of the ipsilateral hemisphere at
(stroke rat that received intravenous hMSCs) (C) compared to placebo-trea
BrdU-positive cells. Bars = 20 μm. Example of autologous hMSCs administe
demonstrates massive infarction involving most subventricular area (arrowh
at the time of intravenous administration of autologous MSCs.occlusion models [13]. Thus, for the criterion of lesion
location, cellular therapy targeting the enhancement of
neurogenesis should be applied to patients with infarc-
tions within the MCA territory.
Preclinical studies in animal models of stroke show
the importance of neurogenesis [14-16]. Newly born
cells migrate to the stroke site, express neuronal and
glial-specific phenotypic markers [17,18], and form
synapses [19]. Transplanted stem cells might enhance
the endogenous neurogenesis that occurs in certain
areas, including the subventricular zone [18,20-22].
However, patients with severe stroke often have severe
damage in periventricular areas, limiting endogenous
neurogenesis (Figure 1). Thus, responses to cell therapy
might differ depending on the degree of damage in
subventricular areas [7].
Patient selection should be performed at an appropri-
ate time [23,24]. Tissue levels of stromal cell-derived
factor 1α (SDF-1α, also known as CXCL12, a chemo-
attractant of mesenchymal stem cells (MSCs)) can vary
among patients with ischemic stroke. Preclinical studies
have suggested that SDF-1α protein expression is associ-
ated with MSC homing and that expression is upregulated
in the infarcted hemisphere for at least 1 month after
stroke [25,26]. We recently showed that serum levels
of SDF-1α are associated with patient response to
MSC treatment [7]. The beneficial effects of cell therapydings in a rat stroke model: T2-weighted MRI at 14 days after transient
d subcortical infarcts sparing the subventricular zone (square). (B,C)
lls (hMSCs) in a stroke rat model: bromodeoxyuridine (BrdU)
day 14 showed enhancement of neurogenesis in the treated group
ted stroke rat (B) (modified from Li et al. [18]). The arrow indicates
red to a patient with stroke (D,E). (D) Diffusion-weighted image
ead). (E) Magnetic resonance angiography reveals persistent occlusion
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and functional integration of transplanted cells with
nearby neurons might be limited by scarring (gliosis)
and Wallerian degeneration, as well as by decreased SDF-
1α levels.
Optimization of treatment
The appropriate type and dose of cells, the mode of
treatment, and the time of application of stem cell ther-
apy remain to be determined [12,27]. These factors
might depend on the target mechanisms of the cell ther-
apy (that is, cell replacement vs restorative effects via
trophic support) [28,29]. The target mechanisms also de-
pend on the characteristics of the patient (for example,
location and chronicity of lesions). Thus, more detailed
guidelines stratified by action mechanisms are needed to
provide maximal benefit to patients with different situa-
tions after a stroke [29].
Stroke lesions usually involve a variety of neuroana-
tomical structures that contain a diversity of cell types
with complex connectivity patterns. True neuronal sub-
stitution requires specific anatomic and functional pro-
files [30]. This is particularly important for therapy using
embryonic or induced pluripotent stem (iPS) cells. With-
out a functional partition, transplanted cells may even
delay the recovery process or result in serious complica-
tions (that is, tumorigenesis of iPS cells transplanted in
ischemic brains) [31]. Stroke causes a variety of second-
ary changes at locations beyond the infarct lesion.
Therefore, anatomical or neurophysiologic studies (for
example, diffusion-tensor imaging) evaluating the rela-
tionship of cell grafts or newly formed cells via neuro-
genesis to post-stroke reorganization are needed.
Outcome measurement
Various outcome parameters have been used in stroke
clinical trials and the selection of functional endpoints
has been the subject of debate. Traditional outcome mea-
sures including the National Institutes of Health Stroke
Scale (NIHSS), modified Rankin score (mRS), or modi-
fied Barthel index (mBI) have advantages, but these end-
points might not be sensitive to the magnitude of
changes in function expected with cellular therapy, based
on the limited efficacy data from previous studies [32].
Therefore, more detailed motor assessments are needed
[33]. Advanced imaging techniques might be useful for
exploring action mechanisms of cell-based therapies or
surrogate outcome measures [32].
Safety concerns
Pretreatment screening with sufficient monitoring is
mandatory for safety. Unlike pharmaceutical drugs,
many stem-cell-based therapies may be produced in aca-
demic laboratories where investigators are unfamiliarwith the relevant regulations [34]. Recently, the US Food
and Drug Administration (FDA) introduced regulations
for stem-cell-based therapies [34], and many efforts have
been made to avoid possible adverse events after stem
cell therapy [32]. The level of regulation and oversight
should be proportional to the degree of risk [35]. Min-
imal culture expansion is defined as an incubation
period not exceeding 60 days and a number of stem cell
culture passages not exceeding 10 days [36].
In addition to screening tests such as cellular viability
and microbiology assays, our previous studies used flow
cytometry to measure the expression of stem cell surface
markers and closely monitored vascular occlusion after
stem cell infusion [6,7]. Moreover, we recently reported
that intra-arterial infusion of autologous MSCs causes
small spotty lesions on diffusion-weighted imaging,
suggesting microembolism even though no patients
showed neurological deterioration [37]. MSCs are larger
than mononuclear cells, prohibiting their intra-arterial
application.
When stem-cell-based products require more than
minimal manipulation, the cells might be grown in cul-
ture with non-human serum [34]. One of the most prob-
lematic unsolved issues in stem cell therapy is the risk of
prion transmission and stimulation of immunogenicity
from the use of fetal calf serum (FCS) or fetal bovine
serum (FBS) in cell culture. FCS and FBS are the most
widely used cell culture growth supplements, and most
clinical trials use human MSCs expanded in FCS or FBS
under FDA-approved protocols. However, these cells
may contain potentially harmful xenogeneic compo-
nents. A fluorescence microscopy study showed that
FCS was not removed from cells, even after extensive
washing with phosphate-buffered saline. A single injec-
tion of a common therapeutic dosage of 1 × 108 MSCs
grown under standard conditions would include ap-
proximately 7 to 30 mg of calf serum protein [38].
Efforts to avoid these risks have included using autolo-
gous serum or serum-free medium [39]. Recently,
Honmou et al. used autologous MSCs culture expanded
ex vivo with an autologous serum. They reported that
the use of autologous human serum rather than FCS
resulted in more rapid expansion of MSCs, which re-
duced cell preparation time and minimized the potential
risk of transmitting viruses, prions, and proteins that
can cause xenogeneic immunogenicity [8]. More re-
cently, Bhasin and colleagues used animal serum-free
media to expand MSCs in chronic stroke [9].
Enhancing the therapeutic effects of stem cells
Limited efficacy of current MSC therapy strategies
The Cochrane group recently assessed the efficacy and
safety of stem cell transplantation compared with conven-
tional treatments in patients with ischemic stroke [40].
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this intervention can improve functional outcomes and
that large, well-designed trials are needed [40]. We re-
cently reported the results of the STARTING (‘STem cell
Application Researches and Trials In NeuroloGy’) study,
a randomized controlled trial of autologous MSC trans-
plantation in patients with subacute severe stroke [7].
Intravenous autologous administration of MSCs cultured
in FBS-containing medium was safe for patients with
stroke over approximately 5 years. However, many pa-
tients remained significantly disabled, although the pro-
portion with mRS 0 to 3 significantly increased in the
MSC group but not in the control group. Thus, further
trials with efforts to enhance the therapeutic effects of
stem cells are needed.
Improving efficacy of MSC therapy and ischemic
preconditioning
Efforts to improve the efficacy of MSCs include ischemic
preconditioning [41,42], blood–brain barrier (BBB) ma-
nipulation [43], and use of genetically modified MSCs
(although this is not feasible in clinical practice) [44,45].
Ischemic preconditioning enhances ischemic tolerance
in various tissues including heart and brain [46,47]. Clin-
ical and preclinical studies of cerebral ischemia demon-
strated that brief, non-lethal ischemia and reperfusion,
referred to as ischemic preconditioning, can have a pro-
tective effect against further episodes of brain ischemia
[46,48]. The cytoprotective effect of preconditioning also
enhances the survival of transplanted stem cells [49]. Is-
chemic preconditioning before transplantation of the
donor cells might initiate survival signaling, creating a
primed and activated state in these cells, and reinforcing
their ability to withstand harsh microenvironments after
transplantation [50]. Hypoxic preconditioning is used in
most preclinical studies, with stem cells exposed to 0.5%
to 3% oxygen for 24 to 72 h.
The number of clinical trials using allogeneic-based
cell therapy approaches is growing [51]. However, treat-
ment using bone marrow stromal cells from stroke rats
was found to promote more improvement of func-
tional outcomes in a rat stroke model compared to
cells from normal rats [52]. Thus, it is conceivable
that MSCs from patients with acute stroke could have
different characteristics from cells from healthy indi-
viduals (either allogeneic or chronic stroke donors),
and culture expansion using serum obtained during
the acute phase of stroke could improve the thera-
peutic effects of MSCs. We recently conducted preclin-
ical studies on the effects of ischemic preconditioning
with ischemic serum on MSC functions (unpublished
data). We evaluated the characteristics of rat MSCs after
culturing with FBS or serum obtained from a rat stroke
model. Compared to FBS, the use of serum from the ratstroke model resulted in more rapid MSC expansion,
which reduced the cell preparation time by increasing
the G2/M phase, decreasing cell death/senescence, in-
creasing trophic factor secretion, and migration capacity.
An important issue in improving the therapeutic
effects of cell therapy in stroke is BBB manipulation. Sys-
temically administered cells might not need to enter the
brain to have therapeutic effects but might be able to act
in the periphery to increase the trophic support that en-
hances endogenous repair mechanisms [53]. However,
even if this is the case, BBB manipulation might be needed
to allow central nervous system entry of endogenous or
graft-derived trophic factors [43].
Methods and design
The STARTING-2 trial
Trial characteristics and design
STARTING-2 is the first study to evaluate the effi-
cacy of MSC treatment in patients with ischemic
stroke. The study is a prospective, randomized, open-
label, blinded-endpoint (PROBE) clinical trial. Both
acute and chronic cases of stroke will be included,
and followed for 3 months after MSC treatment. The
ratio of MSC-treated to control patients is 2:1. Pa-
tients will intravenously receive autologous MSCs
after ex vivo culture expansion with autologous ische-
mic serum obtained as early as possible to enhance
the therapeutic efficacy (ischemic preconditioning).
Selection of patients will be based on clinical and
radiological features, excluding patients with large
involvement of periventricular regions. BBB manipula-
tion using intravenous mannitol before MSC treat-
ment and comprehensive and objective measurements
using multimodal MRI and detailed functional assess-
ments will be performed.
Study objectives
The study tests the hypothesis that patients with ische-
mic stroke with moderate to severe persistent neurologic
deficits will have better outcomes with intravenous
transplantation of autologous MSCs expanded with au-
tologous serum obtained during the acute phase of
stroke than patients receiving standard treatment.
We chose a categorical shift in mRS at 90 days after
treatment as the primary endpoint. The mRS is the pri-
mary endpoint of most stroke clinical trials and shift
analysis has advantages over the classical dichotomized
method for interventions that confer a uniform and
modest benefit to patients over a broad range of stroke
severity [54,55].
The secondary objectives are: (a) to determine the effi-
cacy of MSC therapy by serial assessment of detailed
motor function and by comparing the functional out-
come between MSC therapy and control groups at 90
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therapy in patients with ischemic stroke; and (c) to
evaluate blood and imaging biomarkers that influence
the effects of MSC therapy.Table 2 Inclusion and exclusion criteria
No. Criteria type
Inclusion
1 Men or women (women must be of non-child-bearing potential), age 3
2 Stroke observed within 90 days of the onset of symptoms
3 Radiological:
Relevant lesions within the MCA territory as assessed using DWI.
Maximum diameter of the stroke region in any dimension ≥15 mm
Damage not involving more than a half of the ipsilateral subventricular
4 Clinical (National Institutes of Health Stroke Scale (NIHSS)):
a. Moderate to severe persistent neurologic deficit (NIHSS of 6 to 21 inc
b. New onset of extremity paresis on the affected side, defined as a sco
c. Alert or drowsy but easily arousable as defined by score of 0 to 1 on
d. ‘Slow recovery’ defined as change in NIHSS ≤1 point/3 days
5 Willingness:
a. Reasonable likelihood of receiving standard physical, occupational an
b. Able to participate in the evaluation process to the point of accurate
c. Willing and able to comply with scheduled visits, lifestyle guidelines,
d. Evidence of a personally signed and dated informed consent docum
6 Use of antiplatelet, anticoagulant and/or antithrombotic agents is accep
Exclusion
1 Presence of significant disability prior to the current stroke, defined as p
2 Stroke that is either:
a. Lacunar infarction
b. Hematologic cause of stroke
c. Recurrent or progressive stroke within 1 week at the time of screenin
3 Hematologic disorders or bone marrow suppression
4 Severe medical illness defined as:
a. Severe heart failure
b. Severe febrile illness
c. Hepatic or renal dysfunction
d. Active cancer
e. Any evidence of chronic comorbid condition or unstable acute syste
or limit ability to complete the study
5 Presence of HIV, HBV, HCV, or syphilis on admission blood tests
6 Presence of active depression not adequately controlled that interferes
stroke
7 Presence of dementia prior to the current stroke that is likely to confou
8 Lactating women or pregnant women as determined by positive urine
9 Considered unwilling or unable to comply with the procedures and stu
10 Unwilling to undergo bone marrow aspiration
aWe will measure the degree of involvement of the ipsilateral subventricular zone o
thalamus and head of caudate nucleus and (b) the corona radiate (7-mm upper lev
DWI diffusion-weighted image, HBV hepatitis B virus, HCV hepatitis C virus, hCG humPatient population and evaluation
The clinical trial protocol and consent form were ap-
proved by the Korean FDA and the Institutional Review
Board of the Samsung Medical Center. Written informed0 to 75 years
zonea
lusive)
re of 2 to 4 on the NIHSS motor arm (item 5) or leg (item 6) question.
the NIHSS level of consciousness question (item 1A).
d speech rehabilitation therapy as indicated for post-stroke deficits
assessment
treatment plan, laboratory tests, and other study procedures
ent
table
re-stroke modified Rankin score of 2 or more
g
mic illnesses which, in the investigator’s opinion, could shorten survival
with major activities of daily living immediately prior to the current
nd clinical evaluation
hCG test
dy visit schedule outlined in the protocol
n the initial diffusion-weighted image at two axial levels; (a) the upper
el).
an chorionic gonadotropin, MCA middle cerebral artery.
Kim et al. Trials 2013, 14:317 Page 7 of 12
http://www.trialsjournal.com/content/14/1/317consent will be obtained from all patients and/or their
first-degree relatives. Inclusion and exclusion criteria are
shown in Table 2. During the inpatient rehabilitation
period, all participants will receive conventional rehabili-
tation therapy (physical, occupational, speech/language,
or cognitive rehabilitation therapy as needed). Investiga-
tors blinded to treatment allocation will measure neuro-
logical disability using the NIHSS and functional scores
for mRS and mBI. Motor parameters will be evaluated by
the Motricity index and Fugl-Meyer assessment for gross
motor function, Purdue pegboard test and box and block
test for fine motor function, and functional ambulatory
category and 10-m gait speed tests for mobility, for fur-
ther demonstration and characterization of motor recov-
ery [56-60]. Cognition (Mini-Mental Status Examination
(MMSE)) and quality of life (EuroQol Five Dimensions
(EQ-5D) questionnaire) tests will also be administered.
Any complications or adverse effects observed during the
study period will be described in detail. Flow diagrams of
the study protocol are shown in Figures 2 and 3.
Multimodal brain MRI including structural MRI,
resting-state functional MRI (RS-fMRI) and diffusionFigure 2 Overall study flow of the ‘STem cell Application Researches
before mesenchymal stem cell (MSC) infusion in the MSC group vs 30 daystensor imaging (DTI) and motor evoked potentials
(MEPs) will be performed. Multimodal MRI and MEPs
techniques are described in the Additional file 1. Explor-
ation of biomarkers is planned to further investigate the
mechanisms of action of MSCs and to find predictors
for response to cell therapy. Biomarkers will include
SDF-1α (a chemokine), S100β (a marker of protection
and regeneration), hypoxia-inducible factor 1α (HIF-1α,
a marker of preconditioning), circulating MSCs and
MSC-derived microvesicles, brain-derived neurotrophic
factor (BDNF) and vascular endothelial growth factor
(VEGF) levels, and BDNF genetic polymorphisms
(Table 3) [7,18,61-64].
Preparation and transplantation of MSCs
Methods for bone marrow aspiration, MSC isolation, cell
preparation, and intravenous infusion will be as previ-
ously described, except for the amount of aspirated bone
marrow and the use of autologous serum for ex vivo cul-
tivation of MSCs [6,7]. Briefly, 60 mL of bone marrow
will be aspirated from both posterior iliac crests of each
patient in the MSC group. Aspiration will be performedand Trials In NeuroloGy-2’ (STARTING-2) study. *Indicates 1 day
(± 2 days) after randomization in the control group.
Figure 3 Study protocol of ‘STem cell Application Researches and Trials In NeuroloGy-2’ (STARTING-2) study at each timepoint.
*Indicates 1 day before mesenchymal stem cell (MSC) infusion in the MSC group vs 30 days (± 2 days) after randomization in the control group.
†MSC group only. ‡Will be performed at 14 days after MSC transplantation.
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Bone marrow mononuclear cells will be separated by
Ficoll density centrifugation.
We will use autologous MSCs prepared with autolo-
gous serum, instead of FBS. Serum for ischemic pre-
conditioning will be obtained at the earliest time possible,
immediately after randomization. Less than 500 mL of
whole blood will be drawn at any one time.
Mononuclear cells will be cultured in a 175 cm2
flask (Falcon, Franklin Lakes, NJ, USA) in low-glucose
Dulbecco’s modified Eagle medium (Gibco-BRL, Grand
Island, NY, USA) supplemented with 10% autologous
serum and 20 μg/mL gentamicin in a humidified incuba-
tor at 37°C under 5% CO2. Non-adherent cells will be
removed when the medium is exchanged on days 5 to 7.
When primary MSCs reach 70% to 80% confluence, they
will be harvested and subcultured. Autologous MSCs
will be culture expanded to 1 × 106 cells/kg, the hu-
man dose equivalent to doses found to be effective in
a rat stroke model (1 × 105 to 3 × 106 cells/rat) based
on mean body weight [6]. Immediately before MSC in-
fusion, 100 mL of 20% mannitol will be injected intra-
venously to open the BBB [43]. Expanded autologous
MSCs at 1 × 106 cells/kg (maximum 1.2 × 108) will
be transplanted through the antecubital vein with 5 × 106
cells/mL of normal saline over 10 minutes. We will
use good manufacturing practice conditions (PharmicellCorporation, Seongnam, South Korea) and clinical grade
reagents for cell preparation.
Cell viability will be determined by trypan blue staining at
the end of harvest and before infusion, whether the viability
is greater than 95%. Cell cultures will be tested weekly for
bacterial, fungal, viral, or mycoplasmal contamination. Since
stem cells are highly likely to be differentiated, the surface
expression of CD105, CD90, CD73 (positive MSC markers),
and CD34 (a negative MSC marker) will be measured on
culture-expanded MSCs using flow cytometry (FACScan;
Becton-Dickinson, Rutherford, NJ, USA) before intravenous
transplantation into each patient. Each MSC harvest is
expected to yield a homogenous population of cells with
high expression of positive markers (>90% of cells) and low
expression of the negative marker (<1% of cells).
Randomization and outcomes
Randomization will be in a 2:1 ratio of MSC-
treatment to control patients using computer-generated
random-permuted blocks with blocks of six subjects. The
2:1 ratio was selected to obtain a sufficient number of
participants for explorative analysis in the MSC group.
For the primary outcome analysis, the categorical shift in
mRS at 90 days after treatment will be determined as 0 to
5 mRS levels. Deaths (a mRS score of 6) will be included
in the category of worst outcome (a mRS score of 5). Sec-
ondary and exploratory outcomes are shown in Table 3.
Table 3 Study endpoints
Objective Endpoint
Primary endpoint of efficacy:
Functional outcome Categorical shift in mRS at 90 days after treatment
Secondary endpoints of efficacy:
Disability Change in NIHSS between pretreatment and 90 days post-treatment ≥5 points
improvement or score of 0 to 2 on NIHSS score at 14 days after treatment
Functional outcome mRS ≤2 at 90 days after treatment
Change of mRS between pretreatment and 90 days post-treatment
mBI ≥60 at 90 days after treatment
Change of mBI between pretreatment and 90 days post-treatment
Further demonstration and characteristics of motor
recovery
Change of gross motor function between pretreatment and 90 days post-treatment
Motricity index and Fugl-Meyer assessment (upper, lower)
Change of fine motor function between pretreatment and 90 days post-treatment
Purdue pegboard test (simple) and box and block test
Change of mobility between pretreatment and 90 days post-treatment
Functional ambulatory category and 10-m gait speed
Cognition Change of MMSE between pretreatment and 90 days post-treatment
Quality of life Change of EQ-5D between pretreatment and 90 days post-treatment
Secondary endpoints of safety:
Death All causes of death
Recurrence Recurrent stroke or transient ischemic attack
The immediate reaction Allergic reactions (tachycardia, fever, skin eruption, leukocytosis)
Local complications (hematoma or local infection at the site of bone marrow aspiration)
Vascular obstruction (tachypnea, oliguria, or peripheral vascular insufficiency)
Systemic complications (infections, AST/ALT, or BUN/Cr levels)
Long-term adverse effects possibly related to MSC
treatment
Tumor formation (physical examination, plain X ray, f/u MRI at 90 days after treatment)
Aberrant connections (newly diagnosed seizure or arrhythmia)
Other parameters related to efficacy:
Exploration of biomarkers to further demonstrate the
mechanism of action and genetic profile
SDF-1α (chemokine)
S100β (protection and regeneration)
HIF-1 (preconditioning)
Circulating MSCs and MSC-derived microparticles
BDNF levels and polymorphisms and VEGF levels
Multimodal MRI Resting-state functional MRI and diffusion tensor imaging
Neurophysiologic study Motor evoked potentials
ALT alanine aminotransferase, AST aspartate aminotransferase, BDNF brain-derived neurotrophic factor, BUN blood urea nitrogen, Cr creatinine, DWI diffusion-
weighted image, EQ-5D EuroQol Five Dimensions, HBV hepatitis B virus, hCG human chorionic gonadotropin, HCV hepatitis C virus, HIF hypoxia-inducible factor,
mBI modified Barthel index, MCA middle cerebral artery, MMSE Mini-Mental State Examination, mRS modified Rankin Score, MSC mesenchymal stem cell, NIHSS
National Institutes of Health Stroke Scale, SDF-1α, stromal cell-derived factor 1α, VEGF vascular endothelial growth factor.
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Approximately 60 participants (MSCs vs control group =
40:20) will be studied. This sample size was chosen to
provide a power of 80% and an alpha level of 5% to detect
a common odds ratio of 4.75 (across all cut-off points of
the mRS), which was the result from the STARTING trial
[7]. Possible harmful effects of MSCs will be determined
and assumptions underlying the sample size calculationwill be adjusted by an interim analysis performed by an
independent data and safety monitoring committee (data
from 20 eligible participants in the MSC group) [65].
All randomized participants will be included in the end-
point analyses on an intention-to-treat basis. For primary
outcome analysis, the categorical shift of mRS at 90 days
after treatment will be compared between the MSC and
control groups using the Cochran-Mantel-Haenszel shift
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justed for age, sex, stroke mechanisms, and infarct vol-
ume on fluid attenuation inversion recovery (FLAIR)
imaging 1 day before MSC infusion in the MSC group or
30 days (± 2 days) after randomization in the control
group. In this study, the adjusted result is prespecified as
the primary outcome analysis. Secondary and exploratory
analyses will be performed according to standard statis-
tical methods as appropriate.
Discussion
Preclinical and clinical trials have great potential to im-
prove the therapeutic efficacy and safety of MSCs. In the
STARTING-2 trial, we are incorporating ischemic
preconditioning using ischemic serum, BBB manipula-
tion, and strict selection of candidates for stem cell ther-
apy to improve the therapeutic effects and safety of
MSCs. We anticipate that the study results may provide
better evidence for the effectiveness of MSC therapy in
patients with ischemic stroke.
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